211 related articles for article (PubMed ID: 16163370)
1. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction.
El-Sakka AI
Int J Impot Res; 2006; 18(2):180-5. PubMed ID: 16163370
[TBL] [Abstract][Full Text] [Related]
2. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
[TBL] [Abstract][Full Text] [Related]
3. Clinical course of penile fibrosis in intracavernosal prostaglandin E1 injection therapy: a follow-up of 44 patients.
Chew KK; Stuckey BG
Int J Impot Res; 2003 Apr; 15(2):94-8. PubMed ID: 12789387
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
5. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
Chen RN; Lakin MM; Montague DK; Ausmundson S
J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
[TBL] [Abstract][Full Text] [Related]
6. The causes of patient dropout from penile self-injection therapy for impotence.
Mulhall JP; Jahoda AE; Cairney M; Goldstein B; Leitzes R; Woods J; Payton T; Krane RJ; Goldstein I
J Urol; 1999 Oct; 162(4):1291-4. PubMed ID: 10492182
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China.
He L; Wen J; Jiang X; Chen H; Tang Y
Andrologia; 2011 Jun; 43(3):208-12. PubMed ID: 21486416
[TBL] [Abstract][Full Text] [Related]
9. Cavernous auto-injection therapy with prostaglandin E1.
Nisén H
Ann Chir Gynaecol Suppl; 1993; 206():69-73. PubMed ID: 8291874
[TBL] [Abstract][Full Text] [Related]
10. Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction.
Porst H; van Ahlen H; Block T; Halbig W; Hautmann R; Löchner-Ernst D; Rudnick J; Staehler G; Weber HM; Weidner W
Vasa Suppl; 1989; 28():50-6. PubMed ID: 2609244
[TBL] [Abstract][Full Text] [Related]
11. Incidence of penile pain after injection of a new formulation of prostaglandin E1.
Chen J; Godschalk MF; Katz PG; Mulligan T
J Urol; 1995 Jul; 154(1):77-9. PubMed ID: 7776460
[TBL] [Abstract][Full Text] [Related]
12. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
[TBL] [Abstract][Full Text] [Related]
13. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters.
Vardi Y; Sprecher E; Gruenwald I
J Urol; 2000 Feb; 163(2):467-70. PubMed ID: 10647656
[TBL] [Abstract][Full Text] [Related]
14. What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.
Elhanbly S; Schoor R; Elmogy M; Ross L; Hegazy A; Niederberger C
J Urol; 2002 Jan; 167(1):192-6. PubMed ID: 11743303
[TBL] [Abstract][Full Text] [Related]
15. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
Kunelius P; Lukkarinen O
Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
[TBL] [Abstract][Full Text] [Related]
16. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
Valdevenito R; Melman A
Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
[TBL] [Abstract][Full Text] [Related]
17. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
Loran OB; Segal AS; Shcheplev PA
Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intraurethral liposomal and intracavernosal prostaglandin-E1 in the management of erectile dysfunction.
Engelhardt PF; Plas E; Hübner WA; Pflüger H
Br J Urol; 1998 Mar; 81(3):441-4. PubMed ID: 9523667
[TBL] [Abstract][Full Text] [Related]
19. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction.
Chen J; Godschalk M; Katz PG; Mulligan T
J Urol; 1995 Jan; 153(1):80-1. PubMed ID: 7966797
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
